- Posted by ISPE Boston
- On May 14, 2020
AbbVie has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
“We are pleased to reach this important milestone for the Company, its employees, shareholders and the patients we serve,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and our financial strength will allow us to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon us.”
The transaction significantly expands and diversifies AbbVie’s revenue base and complements existing leadership positions in immunology amd hematologic oncology and provides new growth opportunities in neuroscience. (Source: Allergan Website, 08 May, 2020)